PhD, Epidemiology
MS, Pharmacy Administration
BS, Pharmacy
University of North Carolina at Chapel Hill, Chapel Hill, NC
Alicia Gilsenan applies innovative approaches to the design, conduct, and analysis of both retrospective and prospective epidemiologic studies, most recently focusing on consultation, design, and implementation of postauthorization safety studies. Dr. Gilsenan’s primary areas of expertise are pharmacoepidemiology and therapeutic risk management, as well as the structured benefit-risk assessment of medications, biologics, and devices. She has directed multidisciplinary international teams for large primary and secondary data-collection studies, including multidatabase studies in the United States and Europe, patient registries and site-based studies in the United States, and a risk-minimization evaluation survey. Dr. Gilsenan has published within multiple therapeutic areas, including oncology, gastrointestinal, depression, cardiovascular health, respiratory health, infectious disease, and smoking cessation, as well as in the research areas of risk-minimization measures and structured approaches to benefit-risk assessment, and she is a licensed pharmacist.